Startup Veracyte Presents Data, Prepares to Launch Thyroid MDx Test | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – On the heels of data from a clinical validation study indicating its thyroid cancer test can classify fine needle aspirates as benign with high accuracy, Veracyte said this week it is on schedule to initiate commercialization of the test later this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.